Financial reports
10-Q
2024 Q1
Quarterly report
15 May 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
16 May 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
8-K
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
2 Jan 24
8-K
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating
27 Dec 23
8-K
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Entry into a Material Definitive Agreement
26 Oct 23
8-K
Departure of Directors or Certain Officers
16 Oct 23
8-K
Departure of Directors or Certain Officers
2 Oct 23
8-K
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The- Market under Nasdaq Rules
28 Aug 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
29 Dec 23
S-1/A
IPO registration (amended)
27 Dec 23
S-1/A
IPO registration (amended)
21 Dec 23
S-1
IPO registration
21 Nov 23
424B5
Prospectus supplement for primary offering
28 Aug 23
S-3
Shelf registration
5 Jun 23
S-8
Registration of securities for employees
19 Apr 22
424B4
Prospectus supplement with pricing info
12 Nov 21
S-1MEF
Registration of additional securities for an S-1
9 Nov 21
8-A12B
Registration of securities on exchange
5 Nov 21
Proxies
Other
EFFECT
Notice of effectiveness
28 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
30 Nov 23
EFFECT
Notice of effectiveness
21 Jun 23
UPLOAD
Letter from SEC
15 Jun 23
CORRESP
Correspondence with SEC
15 Jun 23
EFFECT
Notice of effectiveness
10 Nov 21
CERT
Certification of approval for exchange listing
5 Nov 21
CORRESP
Correspondence with SEC
5 Nov 21